Psychedelic Therapy

The U.S. Food and Drug Administration (FDA) has offered positive feedback to CaaMTech, Inc. on its CT-4201 psilocin prodrug program, specifically endorsing the company's approach to addressing "functional unblinding" in its drug trials. This regulatory milestone not only clears the clinical...

Between 1957 and 1967, Argentina experienced a brief yet profound intersection of psychoanalysis and psychedelics, with thousands of therapeutic sessions conducted through the controlled use of LSD and other substances. These treatments, led by pioneering psychotherapists like Dr. Alberto Fontana...

Elon Musk once again made the case for using psychedelics. In a new interview with former CNN anchor Don Lemon, the business magnate said prescription ketamine has helped him with occasional depressive episodes. He also suggested that taking the ketamine has also been beneficial for investors in...

The nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) is partnering with the City and County of Denver, Colorado to provide comprehensive training on psychedelic crisis assessment and intervention to the city's first responders.  The Psychedelic Crisis Assessment and...

Can Psychedelics Increase Sexual Interest And Satisfaction? Study Says Yes And Effects Can Last Months A new study suggests a potential link between the use of psychedelics like magic mushrooms and LSD and improved sexual function up to six months after they have been consumed. Believed to be the...

Psychedelic substances have been used for centuries for spiritual and medicinal purposes. Following their widespread, sometimes chaotic use during the hippie era, they were outwardly and widely banned for all and every purpose.  Nonetheless, researchers have in recent years taken up these...

Studies and reports from the U.S. Department of Veterans Affairs (VA) and other research publications suggest that an estimated 20-30% of U.S. veterans may experience some form of mental health disorder, with depression and anxiety ranking high amongst conditions.  According the New England...

Psychedelic therapy clinic provider Numinus Wellness (TSX:NUMI) (OTC: NUMIF) announced fourth quarter and full year fiscal 2023 results Wednesday after market. The numbers show demonstrable growth on a year-over-year basis, plus reduced cash burn rate for the month of October...

This article was originally published on Psychedelic Spotlight and appears here with permission. Psychiatrists in the United States are increasingly warming up to the idea of treating patients with psychedelics. A new survey set to be published in the Psychedelic Medicine ...

This article was originally published on Psychedelic Spotlight and appears here with permission. Psychiatrists in the United States are increasingly warming up to the idea of treating patients with psychedelics. A new survey set to be published in the Psychedelic Medicine ...

This article was originally published on Microdose and appears here with permission. As the population ages, there is a growing interest in finding new ways to promote healthy aging. Psychedelic therapies have emerged as a promising new approach, with the potential to improve mood, cognition, and...

This article was originally published on Microdose and appears here with permission. Virtual reality (VR) technology is being used in a variety of ways to improve the safety and effectiveness of psychedelic therapy. With costs and access being a major issue, VR can be used to train therapists, help...

Canadian clinical-stage psychedelics company Cybin (NYSE: CYBN) shared its unaudited financial results for the first quarter ended June 30, 2023: Total cash of $6.9 (CA$9.3) million as of June 30, a mere 20.5% from the $31.6 million held on June 30, 2022. Each period began with the company...

This article was originally published on Psychedelic Spotlight and appears here with permission. Psychedelic therapy is growing in popularity, but clinical trials often overlooks the unique needs of diverse racial and ethnic populations As psychedelics increasingly permeate public consciousness,...

Psychedelic therapy is on the rise. June 2022 data from Data Bridge Market Research reports that the US psychedelic drug market could be valued at $9.8 billion by 2029, with a nearly 17% CAGR. Age-old indigenous approaches are now joined by ventures replicating the intent of the practice while...